Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Pacific Biosciences of California Shares Scorched Higher

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Pacific Biosciences of California (NASDAQ: PACB  ) , a developer of genetic analysis technology, skyrocketed higher by as much as 66% after announcing a deal with Roche (NASDAQOTH: RHHBY  ) Diagnostics.

So what: Under the terms of the deal, Pacific Biosciences will develop sequencing systems based on its proprietary single-molecule, real-time technology, which it will develop and sell exclusively to Roche. Roche will then use it for various in vitro human research projects. Pacific Biosciences will receive $35 million up front in cash and has the potential to earn an additional $40 million in development-based milestones.

Now what: Obviously, this is a big win for Pacific Biosciences, which has landed a juggernaut in Roche. Being the No. 1 pharmaceutical company in R&D spending around the globe, the deal doesn't shock me from Roche's standpoint, and it could actually serve as the next step in personalizing cancer care for patients through genetic analysis. Of Roche's 113 ongoing clinical trials, 73 are based in the field of cancer, so it has a big interest in improving patient quality of life and overall drug efficacy. Pacific Biosciences' genetic analysis tools could be that answer.

For Pacific Biosciences, the real allure here is landing the big name in Roche and getting the sorely needed $35 million in cash. Although the company did have $91 million in net cash prior to the deal, it's burning through cash at a rate of around $60 million per year, so this will add a nice cushion to its balance sheet. Ultimately, though, Pacific Biosciences has yet to establish a recurring stream of cash flow through the sale of its diagnostic machines, and until such time as it does, I would probably suggest keeping a safe distance.

Two additional biotech game-changers
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2654433, ~/Articles/ArticleHandler.aspx, 9/29/2016 4:57:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
PACB $9.02 Down -0.04 -0.44%
Pacific Bioscience… CAPS Rating: ***
RHHBY $31.57 Up +0.18 +0.57%
Roche Holding Ltd.… CAPS Rating: *****